ASH 2022 | MRD-guided therapy in patients with intermediate-risk AML compared to unguided cohort using PSM

Jesse Tettero, MD, PhD, Amsterdam UMC, Amsterdam, The Netherlands, shares the findings of a study investigating measurable residual disease (MRD)-guided therapy in patients with intermediate-risk acute myeloid leukemia (AML) compared to unguided cohort using propensity score matching (PSM). In the HOVON-SAKK-132 trial (EUDRACT2013-002843-26), MRD-negative patients received autologous stem cell transplantation, whereas MRD-positive patients received allogeneic stem cell transplantation. Whilst there was no significant difference in relapse-free survival between these two groups, results from the propensity score matching (PSM) analysis showed that patients who are MRD-negative can undergo reduced-intensity conditioning autologous transplantation without an impact on survival outcomes. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.